US · Healthcare · Biotechnology
EPS came in at -0.74 against a street estimate of -0.64 — a miss of 14.8%.
Analysts rate Spyre Therapeutics Inc. a strong buy (10 buy, 1 hold, 0 sell out of 11) with an average price target of $105.79.
| Fund | Stake |
|---|---|
| FMR Inc | 13.57% |
| BlackRock Inc | 6.36% |
| RTW INVESTMENTS, LLC | 4.80% |
| Fairmount Funds Management LLC | 4.63% |
| Perceptive Advisors LLC | 4.36% |
| VR Adviser, LLC | 4.24% |
| Vanguard Capital Management, LLC | 3.52% |
| Driehaus Capital Management LLC | 3.21% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q2 2026 | 2026-06-15 |
| Company announcement · Q2 2026 | 2026-06-01 |
| Board / officer change · Q2 2026 | 2026-05-29 |
| Results announced · Q2 2026 | 2026-05-05 |
| Quarterly report · Q1 2026 | 2026-05-05 |
| Proxy statement · Q2 2026 | 2026-04-10 |
| Annual report FY2025 | 2026-02-19 |
| Quarterly report · Q3 2025 | 2025-11-04 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Spyre Therapeutics Inc. — free to start.
Google PlayApp StoreData updated 2026-08-05.